Citi analyst Samantha Semenkow initiated coverage of Structure Therapeutics (GPCR) with a Buy rating and $60 price target Structure is a clinical-stage biotech focused on developing oral small-molecule therapies for obesity and other metabolic disorders, the analyst tells investors in a research note. The firm says the company’s lead drug, aleniglipron, is an oral small-molecule GLP1R agonist currently in Phase 2b trials for obesity, with data expected by the end of 2025. Citi believes aleniglipron has the potential to be competitive in the obesity market given “encouraging” weight loss data and favorable tolerability. The firm anticipates partnership interest in Structure’s oral pipeline, potentially following the Phase 2b aleniglipron data.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GPCR:
- Buy Rating for Structure Therapeutics: Aleniglipron’s Competitive Edge in the Oral GLP-1 Market
- Eli Lilly jumps as results from weight-loss pill study rival competitor’s
- JPMorgan says Lilly data ‘highly favorable’ for Structure Therapeutics
- Smaller obesity drugmakers jump after Pfizer scraps weight-loss pill
- JPMorgan says Pfizer news ‘mostly a positive’ for Structure, Viking